<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787419</url>
  </required_header>
  <id_info>
    <org_study_id>20-07-0733</org_study_id>
    <nct_id>NCT04787419</nct_id>
  </id_info>
  <brief_title>Probiotics in Pediatric Chronic Cholestasis</brief_title>
  <official_title>The Role of Probiotics in Chronic Cholestasis to Prevent Gastrointestinal Diseases in Pediatric Patients in Cipto Mangunkusumo Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      double blinded RCT (probiotics vs placebo) given to pediatric patients with chronic&#xD;
      cholestasis for 4 weeks duration. baseline characteristics (antropometry, gastrointestinal&#xD;
      symptoms, laboratory examinations) would be compared pre vs post treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In mice model of cirrhosis and ascites, there is an increased intestinal permeability (leaky&#xD;
      gut syndrome), subsequently leads to bacterial translocation. Bacterial translocation&#xD;
      ultimately leads to bacterial overgrowth and increases associated morbidity, for instance,&#xD;
      protracted diarrhea.&#xD;
&#xD;
      This RCT aims to administer probiotics product (lacto-B) in pediatric patients with chronic&#xD;
      cholestasis (cholestasis &gt; 4 weeks, evidenced from laboratory examination results).&#xD;
&#xD;
      method: double-blinded RCT&#xD;
&#xD;
      regimen: (identical, plain silver packaging, with code 0/1 --&gt; revealed by 3rd party upon&#xD;
      study completion)&#xD;
&#xD;
      intervention group: lacto-B 2 sachet per day for 4 weeks (28 days) each sachet of lacto-B&#xD;
      contains: Viable Counts 1 x 107 CFU/g living bacteria in dual pH dependent release coated&#xD;
      (Lactobacillus acidophilus, Bifidobacterium longum, Streptococcus thermophilus), Vitamin C 10&#xD;
      mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Niacin 2 mg.&#xD;
&#xD;
      control group: placebo sachet (saccharum lactis 1gr)&#xD;
&#xD;
      outcomes will be measured following completion of 4 weeks-course of probiotics/placebo&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Both placebo and probiotics have the exact same packaging. batch production numbers are printed, ended with either &quot;0&quot; or &quot;1&quot;. code will be revealed by third party (production and packaging team) upon study completion (following data analysis)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>macroscopic fecal analysis</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>consistency of stool according to Bristol stool chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>microscopic fecal erythrocyte count</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>fecal erythrocyte count per high power field</description>
  </primary_outcome>
  <primary_outcome>
    <measure>microscopic fecal leukocyte count</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>fecal leukocyte count per high power field</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fecal calprotectin</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>fecal calprotectin measured using ELISA technique, reported in micrograms/gram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gut microbiota diversity</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>PCR of gut microbiota diversity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>presence of intestinal bacteria overgrowth</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>measured using hydrogen breath test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>albumin</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>serum albumin level measured in umol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>serum ALT measured in u/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>serum AST measured in u/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALP</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>serum ALP measured in u/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GGT</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>serum GGT measured in u/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bilirubin level</measure>
    <time_frame>28th day of product consumption</time_frame>
    <description>serum total, direct and indirect bilirubin levels measured in u/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of diarrhea</measure>
    <time_frame>day 1- day 28 of product consumption</time_frame>
    <description>any episode of diarrhea within intervention period (&gt;3x/day, loose bowel, or exceeds usual frequency for infants)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antibiotic use</measure>
    <time_frame>day1 - day 28 of product consumption</time_frame>
    <description>any antibiotic consumption as indicated by presence of infection (any organ system)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cholestatic Liver Disease</condition>
  <arm_group>
    <arm_group_label>probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 sachets per day for 4 weeks.&#xD;
1 sachet of probiotics (1gram) contains: Viable Counts 1 x 107 CFU/g living bacteria in dual pH dependent release coated (Lactobacillus acidophilus, Bifidobacterium longum, Streptococcus thermophilus), Vitamin C 10 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Niacin 2 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 sachets per day for 4 weeks.&#xD;
1 sachet of placebo (1gram) contains: saccharum lactis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saccharum lactis</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>probiotics</intervention_name>
    <description>Lactobacillus acidophilus, Bifidobacterium longum, Strepococcus thermophilus</description>
    <arm_group_label>probiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed with chronic cholestasis (&gt;4 weeks evidence of cholestasis from laboratory&#xD;
             evidence)&#xD;
&#xD;
          -  patient/guardian give consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  immunocompromised&#xD;
&#xD;
          -  consumed antibiotic within 2 weeks prior to recruitment time&#xD;
&#xD;
          -  patient already consuming probiotic-added formula (any probiotic supplementation or&#xD;
             formula milk with added probiotic)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>215 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatima Safira Alatas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Child Health Cipto Mangunkusumo Hospital, Faculty of Medicine Universitas Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>stephanie wijaya, MD, MRes</last_name>
    <phone>6281318287185</phone>
    <email>stephaniewijaya90@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>stephanie wijaya, MD, MRes</last_name>
      <phone>081318287185</phone>
      <email>stephaniewijaya90@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Fatima Safira Alatas, MD, PhD</last_name>
      <phone>0811886560</phone>
      <email>safiraalatas@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fatima Safira Alatas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muzal Kadim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonius Hocky Pudjiadi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>dr. Fatima Safira Alatas, SpA(K), PhD</investigator_full_name>
    <investigator_title>Pediatric gastrohepatoenterologist consultant, clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

